MX2020002802A - Anticuerpos de cadena pesada que se unen a ectoenzimas. - Google Patents

Anticuerpos de cadena pesada que se unen a ectoenzimas.

Info

Publication number
MX2020002802A
MX2020002802A MX2020002802A MX2020002802A MX2020002802A MX 2020002802 A MX2020002802 A MX 2020002802A MX 2020002802 A MX2020002802 A MX 2020002802A MX 2020002802 A MX2020002802 A MX 2020002802A MX 2020002802 A MX2020002802 A MX 2020002802A
Authority
MX
Mexico
Prior art keywords
ectoenzymes
heavy chain
chain antibodies
antibodies
antibodies binding
Prior art date
Application number
MX2020002802A
Other languages
English (en)
Inventor
Nathan Trinklein
Schooten Wim Van
Shelley Force Aldred
Kevin Dang
Starlynn Clarke
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of MX2020002802A publication Critical patent/MX2020002802A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los anticuerpos humanos de cadena pesada tales como los UniAbsTM que se unen a ectoenzimas se proporcionan junto con combinaciones de dichos anticuerpos de cadena pesada y anticuerpos de cadena pesada multiespecíficos que se dirigen a epítopos que no se superponen en ectoenzimas, lo que incluye combinaciones sinérgicas. Se incluyen también métodos para elaborar dichos anticuerpos, composiciones que incluyen composiciones farmacéuticas que comprenden dichos anticuerpos y métodos dirigidos al tratamiento de enfermedades o afecciones que se asocian con la expresión de ectoenzimas.
MX2020002802A 2017-09-13 2018-09-13 Anticuerpos de cadena pesada que se unen a ectoenzimas. MX2020002802A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762558147P 2017-09-13 2017-09-13
PCT/US2018/050931 WO2019055689A1 (en) 2017-09-13 2018-09-13 HEAVY CHAIN ANTIBODIES BINDING TO EXOENZYMES

Publications (1)

Publication Number Publication Date
MX2020002802A true MX2020002802A (es) 2020-10-12

Family

ID=63714117

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002802A MX2020002802A (es) 2017-09-13 2018-09-13 Anticuerpos de cadena pesada que se unen a ectoenzimas.

Country Status (13)

Country Link
US (1) US20200207867A1 (es)
EP (1) EP3681908A1 (es)
JP (1) JP2020533362A (es)
KR (1) KR20200044094A (es)
CN (1) CN111133007A (es)
AU (1) AU2018331421A1 (es)
BR (1) BR112020004846A2 (es)
CA (1) CA3075399A1 (es)
IL (1) IL273235A (es)
MX (1) MX2020002802A (es)
RU (1) RU2020112490A (es)
SG (1) SG11202002093TA (es)
WO (1) WO2019055689A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2762835C2 (ru) 2016-08-24 2021-12-23 Тенеобио, Инк. Трансгенные животные, отличные от человека, продуцирующие модифицированные антитела, содержащие только тяжелые цепи
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
JP7665538B2 (ja) 2019-06-14 2025-04-21 テネオバイオ， インコーポレイテッド Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
CN115023441A (zh) * 2019-12-18 2022-09-06 特诺福尔股份有限公司 与cd38结合的重链抗体
EP4592310A2 (en) 2020-03-16 2025-07-30 Angeles Therapeutics, Inc. Novel antigen binding domains and synthetic antigen receptors incorporating the same
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1578447A4 (en) 2002-10-31 2009-06-03 Genentech Inc METHOD AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
EP1978032A3 (en) 2004-07-22 2009-02-18 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
PL2860192T3 (pl) 2005-10-12 2018-03-30 Morphosys Ag Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38
EP2455100A3 (en) 2005-11-07 2012-11-07 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
CA2632424A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
EP2815768A3 (en) 2006-04-05 2015-01-14 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2688834C (en) 2007-06-01 2020-01-07 Ronald Buelow Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
KR101589785B1 (ko) 2009-03-10 2016-01-28 바이오젠 엠에이 인코포레이티드 항-ｂｃｍａ 항체
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US9173961B2 (en) * 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3063173B1 (en) * 2013-10-31 2020-07-29 Sanofi Specific anti-cd38 antibodies for treating human cancers
WO2015063339A1 (en) * 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
JP6775422B2 (ja) * 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
MY187045A (en) * 2014-12-23 2021-08-27 Bristol Myers Squibb Co Antibodies to tigit
CA2986594C (en) * 2015-05-20 2025-06-10 Tufts Medical Center, Inc. Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
MA43219A (fr) * 2015-11-10 2018-09-19 Univ Medical Center Hamburg Eppendorf Polypeptides de liaison d'antigène dirigés contre cd38

Also Published As

Publication number Publication date
IL273235A (en) 2020-04-30
CA3075399A1 (en) 2019-03-21
CN111133007A (zh) 2020-05-08
BR112020004846A2 (pt) 2020-09-15
RU2020112490A3 (es) 2022-03-28
EP3681908A1 (en) 2020-07-22
AU2018331421A2 (en) 2020-05-28
SG11202002093TA (en) 2020-04-29
WO2019055689A1 (en) 2019-03-21
US20200207867A1 (en) 2020-07-02
KR20200044094A (ko) 2020-04-28
AU2018331421A1 (en) 2020-04-30
JP2020533362A (ja) 2020-11-19
RU2020112490A (ru) 2021-10-13

Similar Documents

Publication Publication Date Title
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
ZA202201874B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
MY203971A (en) Anti-lag-3 antibodies and compositions
MX2022001105A (es) Anticuerpos anti tigit.
PH12021553145A1 (en) Multispecific heavy chain antibodies binding to cd22 and cd3
EA201992350A1 (ru) Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MY197866A (en) Anti-cd27 antibodies
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
NZ743049A (en) Anti-cd3-folate conjugates and their uses
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
HK1238261A1 (en) Novel anti-mfi2 antibodies and methods of use